Home | News | Innovation


Qualify phi29 Innovation
CNIO and CSIC receive funding from ISCIII to study early detection of SARS-CoV-2 Diagnostic capacity is one of the limiting factors in the control of the Covid-19 pandemic that is...
CNIO building Innovation
Potential drugs originated at CNIO to be developed by AUM Biosciences in Asia A group of multi-target anti-tumour compounds, the IBL-300 series, discovered at the Spanish...
Telomeres in mouse embryonic fibroblasts Translational
EMBO Molecular Medicine. CNIO researchers find effective drug combinations for glioblastoma in mice Usually, scientists study the molecular biology of cancer to find new treatments, but sometimes, it...
Intestinal stem cells with URI, CNIO Basic Research
Science. CNIO researchers discover a new way to protect against high-dose radiation damage Radiotherapy, a common treatment for cancer, is one of the most effective ways to destroy cancer...
Mouse lymph node Translational
Journal of Experimental Medicine. CNIO researchers assess melanoma progression with a new liquid biopsy technique When the surgeon surgically removes a melanoma, some patients are said to be ‘cancer-free’ and...
CNIO building Basic Research
Cancer Cell. CNIO researchers succeed at removing some types of pancreatic cancer in animal models Researchers from the Experimental Oncology Group, led by Mariano Barbacid at the Spanish National...
DLST protein Translational
The American Journal of Human Genetics. CNIO researchers identify a new gene involved in the development of a rare endocrine tumour Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours: there are only 3-8 cases...
H12O-CNIO Lung Cancer Clinical Research Unit Translational
The New England Journal of Medicine (NEJM). An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients The strategy for triggering the patient’s own immune system to attack cancer, immunotherapy, is...
H12O-CNIO Haematological Malignancies Clinical Research Unit Translational
Haematologica. A new methodology predicts the risk of relapse in patients with acute myeloid leukemia The acute myeloid leukemia (AML) is the most common haematological cancer in adults. With a 5-year...